Pharmacoeconomic potency assignment of targeted agents in the treatment of metastatic colorectal cancer with wild-type Kras
Проблема рака толстой и прямой кишки представляет собой один из важнейших разделов в структуре заболеваемости и смертности от онкологических заболеваний в России и в мире. За последнее десятилетие в этой области произошли значительные изменения, к которым можно отнести: появление оксалиплатина и ири...
Main Authors: | R I Yagudina, I V Poddubnaya, A U Kulikov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IP Habib O.N.
2013-12-01
|
Series: | Современная онкология |
Online Access: | https://modernonco.orscience.ru/1815-1434/article/view/26907 |
Similar Items
-
Pharmacoeconomics of spastic cerebral palsy
by: R. I. Yagudina, et al.
Published: (2018-02-01) -
Pharmacoeconomics of HIV-infection
by: R. I. Yagudina, et al.
Published: (2018-02-01) -
Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
by: Patel SB, et al.
Published: (2015-12-01) -
FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
by: Caglayan Geredeli, et al.
Published: (2018-03-01) -
Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients.
by: Yu-Lin Lin, et al.
Published: (2014-01-01)